Six Clinical Sites Across the U.S. Engaged in Phase 1b Study
Phio Pharmaceuticals Corp. Completes Enrollment for PH-762 Trial
Marlborough, Massachusetts–(Newsfile Corp. – November 19, 2024) – Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company exploring new pathways towards a cancer-free future, today announced it has completed the enrollment of its second patient cohort in its PH-762 Phase 1b dose-escalating clinical trial, and added a sixth clinical site in San Diego, CA. Phio recently presented new data from the ongoing clinical trial showing that, of the two patients who have completed treatment in the second dose cohort, one patient with cutaneous squamous cell carcinoma achieved a complete response (100% tumor clearance) while a second patient with squamous cell carcinoma achieved a partial response (90% tumor clearance).
Phio Pharmaceuticals Corp., a leader in the field of biotechnology, is making significant progress in the fight against cancer with its PH-762 Phase 1b clinical trial. The addition of a sixth clinical site in San Diego, CA, highlights the company’s commitment to expanding access to cutting-edge treatments for patients across the United States. The recent data presented by Phio is promising, showing positive outcomes for patients with different types of squamous cell carcinoma.
The success of the second patient cohort in achieving tumor clearance is a testament to the potential of PH-762 as a targeted therapy for cancer. By exploring new pathways and developing innovative treatments, Phio Pharmaceuticals Corp. is paving the way for a future where cancer can be eradicated.
How Will This Affect Me?
As a current or future cancer patient, the advancements made by Phio Pharmaceuticals Corp. in their PH-762 Phase 1b trial offer hope for more effective and targeted treatment options. The positive results seen in patients with squamous cell carcinoma indicate that PH-762 has the potential to improve outcomes and quality of life for individuals battling this type of cancer.
How Will This Affect the World?
The progress made by Phio Pharmaceuticals Corp. in their clinical trials has far-reaching implications for the world of cancer research and treatment. The promising data presented by the company could lead to the development of new therapies that target specific types of cancer with greater precision, ultimately contributing to a future where cancer is no longer a deadly disease.
Conclusion
Phio Pharmaceuticals Corp.’s successful enrollment of its second patient cohort in the PH-762 Phase 1b trial and the addition of a sixth clinical site mark important milestones in the fight against cancer. The positive outcomes observed in patients with squamous cell carcinoma demonstrate the potential of PH-762 to revolutionize cancer treatment and bring us closer to a cancer-free future.
